Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,462 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Solid Neoplasm Clear all
Active, not recruiting Phase 1 Interventional

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

NCT06026254
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IMSA101, Immune Checkpoint Inhibitor
Drug
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Scottsdale, Arizona • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 29, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional Results available

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

NCT04167137
View directory record Official record
Conditions
Metastatic Solid Neoplasm, Lymphoma
Interventions
SYNB1891, Atezolizumab
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

NCT00459836
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PR-104, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Proacta, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors

NCT00021346
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional

Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00049088
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00052273
View directory record Official record
Conditions
Adult, Solid Tumor
Interventions
capecitabine, enzastaurin hydrochloride
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional

Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

NCT01642342
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, pharmacological study, recombinant albumin fusion protein sEphB4-HSA
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 29, 2026, 2:52 AM EDT
Withdrawn Not applicable Interventional

Yoga for Solid Tumor

NCT03728205
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Yoga
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 29, 2026, 2:52 AM EDT
Active, not recruiting Phase 1 Interventional

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

NCT03993873
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
Interventions
elzovantinib (TPX-0022)
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
La Jolla, California • Orange, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

NCT00002994
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
interleukin 2, rhuMAb
Biological
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
34
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 29, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559
View directory record Official record
Conditions
Solid Tumor
Interventions
Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Duarte, California • Santa Monica, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 2:52 AM EDT
Terminated No phase listed Observational

Cancer Occurrence and Outcome in Young Patients Undergoing Cancer Treatment at the Vanderbilt-Ingram Cancer Center

NCT00670605
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
medical chart review, study of socioeconomic and demographic variables
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
15 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Stereotactic Radiosurgery for Patients With Hepatic Metastases.

NCT00547677
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Inhaled Doxorubicin in Treating Patients With Primary Lung Cancer or Lung Metastases

NCT00004930
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
doxorubicin hydrochloride
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

NCT02496065
View directory record Official record
Conditions
Tumors, Breast
Interventions
BLZ-100
Drug
Lead sponsor
Blaze Bioscience Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Bellevue, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 29, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481
View directory record Official record
Conditions
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer
Interventions
ABBV-400, Itraconazole (ITZ), Bevacizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • San Francisco, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 3 Interventional

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

NCT00003600
View directory record Official record
Conditions
Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa, placebo
Biological · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
20
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 29, 2026, 2:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations

NCT00169312
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
behavioral dietary intervention, dietary intervention, educational intervention, internet-based intervention, preventative dietary intervention, evaluation of cancer risk factors
Behavioral · Dietary Supplement · Other + 1 more
Lead sponsor
Josephine Ford Cancer Center
Other
Eligibility
21 Years to 65 Years
Enrollment
2,619 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Denver, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Terminated Phase 1 Interventional

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors

NCT05346484
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Interventions
CF33-hNIS, Pembrolizumab, Modified FOLFOX
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Active, not recruiting No phase listed Observational

Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers

NCT02041416
View directory record Official record
Conditions
Cancer, Solid Tumor, Hematologic Malignancy
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 29, 2026, 2:52 AM EDT
Completed Phase 1 Interventional

Carboxyamidotriazole and Ketoconazole in Treating Patients With Advanced Cancers

NCT00003249
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboxyamidotriazole, chemotherapy, ketoconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 29, 2026, 2:52 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

NCT06784193
View directory record Official record
Conditions
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer, Fulvestrant, Palazestrant
Interventions
OP-3136, Fulvestrant, Palazestrant
Drug
Lead sponsor
Olema Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Gilbert, Arizona • Aurora, Colorado • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 29, 2026, 2:52 AM EDT
Withdrawn Phase 1 Interventional

ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer

NCT00006106
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Head and Neck Cancer, Oropharyngeal Cancer
Interventions
cisplatin, fluorouracil, ONYX-015
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 29, 2026, 2:52 AM EDT